More than 55 million people worldwide are living with dementia, and that number continues to grow as more populations become super-aged. Current treatments can help manage symptoms, such as memory loss and confusion, but there is still no cure; most therapies can’t stop disease progression or repair the damage caused in the brain.
TheraVac Biologics is developing therapeutic vaccines designed to help the body’s immune system recognize and respond to the brain changes that contribute to Alzheimer’s disease and frontotemporal dementia. By targeting the buildup of harmful proteins and chronic inflammation in the brain, TheraVac’s vaccines have the potential to address important drivers of neuronal damage and cognitive decline while offering a more accessible and longer-lasting treatment approach.
